Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2022-12-13 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PTX 7 pages 29.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Prescient Therapeutics Limited dated December 14, 2022, regarding the quotation of securities issued due to the exercise of options or conversion of convertible securities. It details the number and type of securities issued, the exercise of options, and the resulting changes in issued capital. The content is focused on the issuance and quotation of shares following option exercises, which is a capital structure change. There are no financial statements, management discussion, or audit information present. The document fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2022-12-13 English
Section 708A Cleansing Notice 2 pages 492.2KB
Regulatory Filings Classification · 95% confidence The document is a Section 708A Cleansing Notice issued by Prescient Therapeutics Limited under the Corporations Act 2001 (Cth). It confirms the issuance of shares following the exercise of options and compliance with disclosure requirements. The content is a regulatory announcement about share issuance and compliance, not a financial report or detailed financial data. The document length is 5425 characters, which is relatively short and primarily serves as a formal notice rather than a report. There is no financial statement, management discussion, or detailed financial analysis present. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-13 English
Notification of cessation of securities - PTX 5 pages 26.0KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Prescient Therapeutics Limited dated December 14, 2022, detailing securities that have ceased, specifically options that have expired or lapsed. It includes tables showing the number of securities ceased and the issued capital following these changes. The content focuses on changes in the company's issued capital and securities status rather than financial results, management changes, or regulatory certifications. There is no indication of a full financial report, audit, or earnings release. The document is a formal notification about securities cessation, which aligns with announcements related to capital structure changes or share issues. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief notice but a substantive announcement about capital changes.
2022-12-13 English
Change of Director's Interest Notice 3 pages 273.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including shares and options acquired or disposed of, and the nature of these changes (e.g., exercise of employee options). There is no financial performance data, earnings information, or report publication mentioned. The content is focused on insider share transactions by a director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2022-12-13 English
Application for quotation of securities - PTX 7 pages 28.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Prescient Therapeutics Limited regarding the quotation of securities resulting from the exercise of options or conversion of convertible securities. It details the number of securities to be quoted, issue dates, and other issuance specifics. The document references ASX Listing Rules and includes tables of securities issued and outstanding. There is no financial performance data, management discussion, or audit information. The content is focused on capital changes due to securities issuance and quotation. Therefore, this fits the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains detailed issuance information, not just a brief notice or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2022-12-08 English
Chair's Address to the 2022 Annual General Meeting 5 pages 1.5MB
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting – Chair Address' and is dated 29 November 2022. It is a letter from the Chair to shareholders discussing the company's progress, strategic partnerships, clinical developments, and market conditions. The content is typical of a speech or address given at an Annual General Meeting (AGM). There is no detailed financial data, no comprehensive financial statements, nor is it a transcript of a call or a regulatory filing. The document is a presentation or material shared during the AGM, consistent with the AGM Information category. The length (over 14,000 characters) supports it being a substantive address rather than a brief announcement. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-11-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.